Comprehensive review of thymosin alpha-1 covering hepatitis B/C trials, cancer immunotherapy, HIV studies, vaccine enhancement, and safety data — positioning it as a versatile immune-modulating peptide drug.
Multi-indication versatilityPhase III HCV, Phase II HBV, cancer survival benefit, and HIV immune restoration — all with minimal side effects from a single peptide drug
What the researchers found
Thymosin alpha-1 demonstrates clinical efficacy across hepatitis B, hepatitis C (with IFN), cancer (with chemo), and potentially HIV, with excellent tolerability and a favorable safety profile across all studied indications.
Why it matters
This is the definitive clinical reference for thymosin alpha-1, covering everything a prescriber or researcher needs to know about this peptide drug's established and emerging clinical applications.
How the study worked
Comprehensive pharmaceutical review covering pharmacology, pharmacokinetics, all clinical trial data (Phase I-III), adverse effects, and dosing across multiple indications.
What this study cannot tell us
Detailed 2002 review. Some indications had limited trial sizes. Hepatitis C treatment has since been revolutionized by DAAs. Some clinical comparisons were not placebo-controlled.
How to read the evidence
Moderate to strong evidence from a comprehensive pharmaceutical review incorporating all available clinical trial data across multiple indications.
When this study was published
Published in 2002. Thymosin alpha-1 (Zadaxin) is now approved in 30+ countries, primarily for hepatitis B and as an immune adjuvant.
The bigger picture
Thymosin alpha-1 is one of the most clinically advanced immune peptide drugs, with a breadth of applications spanning infectious diseases, cancer, and immune reconstitution that few single agents achieve.
Questions still open
- Could thymosin alpha-1 enhance checkpoint immunotherapy for cancer?
- Should thymosin alpha-1 be used for immune reconstitution after COVID-19?
- What is the global regulatory trajectory for new indications?
Common questions
What diseases can thymosin alpha-1 treat?
Is it safe?
Read the original research
Thymosin alpha1. SciClone Pharmaceuticals.
Current opinion in investigational drugs (London, England : 2000), 3(5), 698-707
Citation
Billich, Andreas. (2002). Thymosin alpha1. SciClone Pharmaceuticals.. Current opinion in investigational drugs (London, England : 2000), 3(5), 698-707.